Earnings call: Sarepta Therapeutics posts strong Q1 with robust revenue growth By Investing.com

Published on 2 May 2024 on Investing.com

Sarepta Therapeutics, Inc. (NASDAQ: NASDAQ:SRPT), a leader in precision genetic medicine for rare...

Read the rest of the article

Start tracking your investments with Statfolio

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Chief Customer Officer Dallan Murray has sold a total of...

Investing.com 7 May 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) just released its quarterly report and things are lookin...

Simply Wall St. via Yahoo Finance 5 May 2024

The U.S. FDA's accelerated approval drug process is under fire from a prominent medical expert wh...

Seeking Alpha 2 May 2024

Sarepta Therapeutics, Inc. SRPT reported adjusted earnings of 73 cents per share in the first qua...

Zacks via Yahoo Finance 2 May 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcript May 1, 2024 Sarepta The...

Insider Monkey via Yahoo Finance 2 May 2024

Sarepta Therapeutics, Inc. (NASDAQ: NASDAQ:SRPT), a leader in precision genetic medicine for rare...

Investing.com 2 May 2024

With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab...

Benzinga 2 May 2024

Investors are always looking for stocks that are poised to beat at earnings season and Sarepta Th...

Zacks via Yahoo Finance 30 Apr 2024

Designed to provide broad exposure to the Small Cap Blend segment of the US equity market, the iS...

Zacks via Yahoo Finance 8 Apr 2024

A three-story office building in the Easton area has changed hands.

The Business Journals 5 Apr 2024